The aim of this study was to investigate the value given by patients’ and caregivers’ to components of composite outcomes in pulmonary arterial hypertension (PAH) clinical trials. There were 335 participants, of which 257 were patients with pulmonary arterial hypertension. The study findings revealed that most outcomes were considered of major or mild-to-moderate importance to patients and that death was the only outcome considered of critical importance.
For further details about this study check this link.
What is very interesting is that the authors conclude that integrating patients’ perception in the elaboration of clinical trials is essential and that “new inter-professional models with greater collaboration among healthcare professionals and partnership with patients could better respond to chronic disease patients’ evolving medication needs.
Authorisation to use the content of the article submitted to the BMJ Publishing Group, see licence at this link
Citation
Mai V, Gosselin C, Tremblay É, Rompré G, Lajoie AC, Weatherald J, Lega JC, Bonnet S, Provencher S. Patients’ perceptions on clinical trials outcomes in pulmonary arterial hypertension therapy. Thorax. 2023 May 4:thorax-2022-219490. doi: 10.1136/thorax-2022-219490. Epub ahead of print. PMID: 37142420.
Disclaimer
While every possible effort will be taken to ensure that the Pulmonary Hypertension Knowledge Sharing Platform content is accurate and up-to-date, it may still include opinions of experts that are the best knowledge at the time of publication but may now be outdated, and materials that are otherwise inaccurate or incomplete. We invite visitors to consult with their health care professionals before making any decisions based upon them.